Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer

Breast Cancer Res Treat. 1988 Apr;11(1):67-70. doi: 10.1007/BF01807560.

Abstract

Serum sex hormone binding globulin (SHBG) was measured in 21 pre and 39 postmenopausal women with advanced breast cancer before treatment and 1, 3, 6, 9 and 12 months after ovarian irradiation or during continuous administration of tamoxifen at a dose of 10 mg twice daily, respectively; some patients received additional prednisolone at a dose of 5 mg twice a day. Ovarian irradiation was associated with a 25% reduction in serum SHBG levels 3 to 6 months after treatment whilst patients on tamoxifen experienced a rise of about 80% in serum SHBG levels after 1 to 3 months. In postmenopausal women prednisolone markedly dampened the effect of tamoxifen, reducing a 80% rise to about 20%. There was no relationship between SHBG levels and response to treatment.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Breast Neoplasms / blood
  • Breast Neoplasms / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Menopause
  • Ovary / radiation effects
  • Prednisolone / therapeutic use*
  • Radiotherapy Dosage
  • Sex Hormone-Binding Globulin / metabolism*
  • Tamoxifen / therapeutic use*

Substances

  • Sex Hormone-Binding Globulin
  • Tamoxifen
  • Prednisolone